The intricate interplay between HIFs, ROS, and the ubiquitin system in the tumor hypoxic microenvironment

Alterations in protein ubiquitination and hypoxia-inducible factor (HIF) signaling both contribute to tumorigen-esis and tumor progression. Ubiquitination is a dynamic process that is coordinately regulated by E3 ligases and deubiquitinases (DUBs), which have emerged as attractive therapeutic targets. HIF expression and transcrip-tional activity are usually increased in tumors, leading to poor clinical outcomes. Reactive oxygen species (ROS) are upregulated in tumors and have multiple effects on HIF signaling and the ubiquitin system. A growing body of evidence has shown that multiple E3 ligases and UBDs function synergistically to control the expression and activity of HIF, thereby allowing cancer cells to cope with the hypoxic microenvironment. Conversely, several E3 ligases and DUBs are regulated by hypoxia and/or HIF signaling. Hypoxia also induces ROS production, which in turn modulates the stability or activity of HIF, E3 ligases, and DUBs. Understanding the complex networks be-tween E3 ligase, DUBs, ROS, and HIF will provide insights into the fundamental mechanism of the cellular re-sponse to hypoxia and help identify novel molecular targets for cancer treatment. We review the current knowledge on the comprehensive relationship between E3 ligase, DUBs, ROS, and HIF signaling, with a particular focus on the use of E3 ligase or DUB inhibitors in cancer.(c) 2022 Elsevier Inc. All rights reserved.

Automated summary

Alterations in protein ubiquitination and HIF signaling contribute to tumorigenesis and tumor progression. ROS upregulation in tumors has multiple effects on HIF signaling and the ubiquitin system. Multiple E3 ligases and UBDs work together to regulate the expression and activity of HIF, helping cancer cells cope with hypoxia. Understanding the complex networks between E3 ligase, UBDs, ROS, and HIF provides insights into the cellular response to hypoxia and identifies novel molecular targets for cancer treatment.